Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Leishmania Major P27 Gene Knockout As a Novel Live Attenuated Vaccine Candidate: Protective Immunity and Efficacy Evaluation Against Cutaneous and Visceral Leishmaniasis in Balb/C Mice Publisher Pubmed



Elikaee S1 ; Mohebali M1, 2 ; Rezaei S1 ; Eslami H3 ; Khamesipour A4 ; Keshavarz H1, 2 ; Eshraghian MR5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Research Center for Endemic Parasites of Iran, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Source: Vaccine Published:2019


Abstract

Leishmaniasis is a growing health problem in many parts of the world and efforts to find vaccine against the disease are a public health priority. Live attenuated vaccines are the gold standard for protection against intracellular pathogens such as Leishmania spp. Defined genetic alteration of the Leishmania genome can be achieved using a gene-targeted disruption strategy that allows for the selection of parasites lacking genes essential for long-term survival and virulence. Previously, we demonstrated that genetically modified live attenuated Leishmania major, lacking the p27gene (Lmp27−/−) is safe and induces cellular immunity in BALB/c mice. p27 is a component of the COX complex that is responsible for ATP synthesis. In the current study, the Lmp27−/− strain was assessed as a live attenuated vaccine. Overall protective immunity and efficacy were evaluated at various time periods following Leishmania major (L. major) and Leishmania infantum (L. infantum) challenges separately in BALB/c mice. Cytokine and anti-Leishmania antibody levels, splenocyte proliferation, delayed type hypersensitivity (DTH), skin lesion development, and parasite burden in the liver and spleen were the measured variables. The results demonstrated that immunized mice had a significant T-helper type 1 (Th1) response, smaller skin lesions and lower parasite burdens in their liver and spleens following a L. major challenge. Furthermore, the Lmp27−/− mutant also granted cross-protection against L. infantum infection. These results suggest that immunization with Lmp27−/− parasites provide significant protective immunity and efficacy against infection with homologous as well as heterologous species of Leishmania parasites. © 2019 Elsevier Ltd
Experts (# of related papers)